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Abstract
Background: Migration among persons living with HIV (PLWH) seeking HIV care is common; however its effect on
health outcomes in resource-rich settings is not well understood. We conducted a retrospective cohort study to
quantify the extent to which PLWH are migrating for care within British Columbia (BC) and its association with
virologic suppression and mortality.
Methods: Eligible PLWH first initiated treatment in BC between 2003 and 2012 (N = 3653). Analyses were performed at
the regional Health Authority (HA) level (N = 5). For privacy reasons, we kept the name of these HAs anonymous and
we re-named these five regions as 1 to 5. PLWH were classified according to the HA where they resided and received
HIV care. We calculated all-cause mortality rates, life expectancies (at age of 20 years), and in, out and net migration
rates across HAs using different demographic methods. Virologic suppression (<50 copies/mL) was based on the last
viral load available for each PLWH. We also calculated per-capita rates (per 100 PLWH ever on cART) for each HA by
dividing the number of PLWH by the number of physicians attending this population.
Results: There is considerable heterogeneity in physician availability across all HAs, with per-capita rates (per 100 PLWH
ever on cART) ranging from 2.2 (HA 1) to 12.7 (HA 3) based on the HA PLWH received care. We observed that in HAs 1,
4, and 5, between 4 and 10 % of PLWH migrated to HA 3 (i.e. the largest urban center) to receive care, and for HA 2
this proportion increased to 21 %. In HA 3, 77 % of its PLWH residents remained in the same HA for their
care. Migrating to a larger center for HIV care was not associated with higher rates of viral load suppression;
it was significantly associated with lower mortality rates and higher life expectancies.
Conclusions: A thorough understanding of the reason(s) for these significant migration rates across BC will
be critical to inform resource allocation and optimize the impact of HIV treatment.
Background
In the early days of combination antiretroviral therapy
(cART), HIV treatment options and access was limited
and treatment guidelines were relatively complex [1]. As
a result, HIV care was resource intense and required a
high level of provider expertise; as such, services tended
to be concentrated in specialized clinics in large urban
centres. Since then, cART has evolved substantially,
with an increased number of simplified, safer, better-
tolerated and more effective treatment options [2]. The
evolution of cART has made the goal of lifelong virologic
suppression a realistic possibility, and has enabled the
emergence of a bold new target for the global control of
HIV/AIDS: the 90-90-90 Target [3]. In order to meet the
90-90-90 Target, persons living with HIV (PLWH) will
necessitate regular access to an experienced care provider
to fully adhere and benefit from treatment [4].
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Since HIV is now considered a chronic manageable dis-
ease, therapeutic guidelines have been simplified and HIV
care has increasingly shifted to decentralized community-
based medical practices [5, 6]. Studies looking at patient
outcomes for other chronic diseases have shown that
access to community-based care offered by a continu-
ous provider was associated with increased attendance
at follow-up appointments and better disease control,
which translated into fewer emergency department visits
and hospitalizations, as well as decreased mortality [7–11].
Patients also reported higher satisfaction with their care
when it is available locally and offered by a continuous
provider or a team of providers [7, 11, 12].
The success that cART has achieved in improving
disease outcomes among PLWH can be potentially hin-
dered by patient migration, since migration has been iden-
tified as a possible source of loss to follow up in several
studies, particularly in resource-limited settings [13–22].
Typically, it has been reported that PLWH tend to migrate
towards urban centres following an HIV diagnosis to seek
treatment and care [23]. It has been suggested that this
migratory pattern is driven by the increased HIV stigma
and the lack of access to specialized medical care in small
communities [24, 25]. Regardless of the reason, migration
has been associated with incomplete adherence to cART
and higher mortality [26, 27]. However, the association of
patient migration, especially when they routinely migrate
for care, with cART outcomes in resource-rich settings is
not well understood.
Migrating for care is particularly concerning given
the existing evidence on the importance of community-
based continuous care for improving other chronic disease
outcomes. We, therefore, conducted the present retro-
spective cohort study to quantify the extent to which
PLWH are migrating for their care within British
Columbia (BC), Canada, and its association with HIV
virologic suppression and all-cause mortality. We hy-
pothesized that receiving community-based HIV care
is associated with better health outcomes.
Methods
Data sources
Data from eligible PLWH were extracted from the BC
Centre for Excellence in HIV/AIDS (BC-CfE) Drug
Treatment Program monitoring and evaluation system.
Since October 1992, the distribution of antiretrovirals in
BC has been the responsibility of the BC-CfE. Antiretro-
viral drugs are distributed to all PLWH in BC according
to specific guidelines generated by the Therapeutic
Guidelines Committee. These guidelines have remained
consistent with those put forward by the International
AIDS Society-USA since 1996 [1, 2].
Eligible PLWH were cART naïve, ≥20 years old, en-
rolled between January 1, 2003 and December 31, 2012
and followed: (1) until December 31, 2013 (if alive); (2)
until the last contact date if they were lost to follow-up
or if they moved out of BC); or (3) until the date of
death. These individuals started cART consisting of two
nucleoside reverse-transcriptase inhibitors as backbone,
plus either a non-nucleoside reverse-transcriptase inhibi-
tor or a boosted protease inhibitor. They must also have
had a CD4 count and plasma viral load measurement
within six months of the initial antiretroviral date.
BC is a geographically large province with major re-
gional differences in population demographic and socio-
economic characteristics, and in health needs. As such,
the government divided the province in five health au-
thorities (HA) [28], which are responsible for the man-
agement and delivery of health services in geographically
defined subpopulations in BC. Typically, in the BC-CfE,
physicians monitor PLWH on cART at intervals no lon-
ger than three months, at which time, prescriptions are
renewed or modified, and PLWH’ addresses are updated
in the BC-CfE database. Every year, physicians are asked
to update their addresses at the College of Physicians
and Surgeons of BC, and their addresses are continu-
ously updated in our database. In this study, PLWH and
their physician addresses were then used to classify indi-
viduals according to the five HAs where PLWH resided
or where they received medical care.
To provide a context to the readers, the five BC HAs
are heterogeneous regarding several socio-economic as-
pects including income, housing, employment, poverty,
and ethnicity. These HAs are also heterogeneous in the
way they deliver care to the BC population. In this study,
we kept the name of these HAs anonymous for privacy
reasons and we re-named these five regions as 1 to 5.
Based on the latest Regional Socio-Economic Index cal-
culated by the BC government, HA 3 had by far the
highest and HA 5 the lowest socio-economic index,
while the other three HAs had very similar intermediate
socio-economic indexes. It is also noteworthy that HA 3
has the highest number of clinical staff, prescribing phy-
sicians, comprehensive HIV supportive services and it
hosts the BC-CfE.
Outcome variables
Crude, cART era and HA-specific all-cause mortality
rates (per 1000 person-years of follow-up) were ob-
tained for PLWH who have ever started treatment. These
mortality rates were calculated dividing the number of
deaths (all causes) by the number of person-years of
follow-up; corresponding 95 % confidence intervals and
test for the equality for these rates were based on the
Fisher’s exact test [29]. Deaths occurring amongst PLWH
during the follow-up period were identified on a daily
basis from physician reports and through monthly record
linkages carried out with the BC Vital Statistics Agency.
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Person-years for PLWH on treatment were calculated
from the date of first cART to December 31, 2013, or the
date of death or censoring.
cART era was defined according to the year of first
treatment (2003–2007 and 2008–2012) and based on
different treatment rollout periods in BC since 2003;
with the most significant period being between 2009 and
2012 when the BC government funded the STOP HIV/
AIDS initiative to further address the HIV epidemic in
the province [http://stophivaids.ca]. HAs 3 and 5 were
the regions targeted by this initiative during the study
period. Age-specific mortality rates were used to calcu-
late life expectancies, and they were specifically obtained
for the age groups 20–29, 30–34, 35–39, 40–44, 45–49
and 50+ years to account for the age distribution of
PLWH in our cohort. The construction of these life ta-
bles and their respective 95 % confidence intervals (CIs)
were obtained as outlined in Chiang [30]. Additionally,
we assessed whether these individuals were suppressed
(i.e. a plasma viral load <50 copies/mL) based on the last
viral load available during their follow-up. Note that all
plasma viral load measurements in BC are centrally
done at the St Paul’s Hospital virology laboratory.
To correct the data for loss to follow-up, we built
an explanatory multivariable logistic regression model
(modeling the probability of death) among individuals
whose status at the end of follow-up was either alive
or dead. The final model contained the variables
adherence, age, year of first cART, follow-up time,
baseline CD4 cell count and plasma viral load. The
area under the receiver operating characteristic curve
(AUC-ROC), a measure of goodness of fit measuring the
model’s ability to discriminate between those PLWH who
died and those who did not, ranges from 0.50 (no discrim-
ination) to 1.00 (perfect discrimination) [31]. In this
model, we obtained an AUC-ROC of 0.91, which is
considered an outstanding discrimination. Therefore, we
applied the estimated model coefficients to the data of
PLWH who were lost to follow-up to calculate their
respective probability of being dead by the end of follow-
up. The cut-off used for these estimated probabilities was
one and, in this case, only PLWH whose estimated prob-
ability was equal to one were considered dead at the end
of follow-up. Given that these individuals do not have an
exact date of death, we considered their last contact date
as the date of death.
Migration indicators
For the migration analyses, we first calculated per-capita
rates (per 100 PLWH ever on cART) for each HA by
dividing the number of PLWH by the number of physi-
cians attending this population. This measure describes
the heterogeneity in physician availability across the dif-
ferent HAs. We then defined migration for care as the
movement from the HA where the PLWH resided to the
HA that he/she received care. Note that this move-
ment (within short and long distances) is temporary
and may be for voluntary or involuntary reasons. A
number of migration indicators were used to study
the trends across HAs during 2003–2012 [32, 33]. First,
we assessed internal migration of different HAs by com-
paring the HA where they received care to the HA where
the PLWH resided. Second, we calculated three common
migration rates for each HA defined as:
 In-migration rate: IHA i½ PHA i½   1000, where IHA[i] is the
number of in-migrants during a specified time for
the ith HA (i = 1, …,5) and; PHA[i] is the population
of the ith HA at the mid-point of the migration
interval. In lay terms, in this study, the in-migrants
are the ones who leave the HA that they resided to
receive care in another HA.
 Out-migration rate: OHA i½ PHA i½   1000, where OHA[i] is the
number of out-migrants during a specified time for
the ith HA (i = 1, …,5) and; PHA[i] is defined above.
In lay terms, in this study, the out-migrants are the
ones arriving from different HAs to receive care in
the HA that is not their residence.
 Net-migration rate: IHA i½ −OHA i½ PHA i½   1000, where IHA[i],
OHA[i] and PHA[i] are defined above.
All analyses were performed using SAS software
version 9.3 (SAS, Cary, NC). The BC-CFE received
approval for this study from the University of British
Columbia ethics review committee at the St Paul’s
Hospital, Providence Health Care site (P05–123). The
study complies with the BC’s Freedom of Information
and Protection of Privacy Act. The study was conducted
primarily using anonymized administrative databases,
and therefore informed consent was not required.
Results
Baseline characteristics
This study was based on data of 3653 PLWH who
initiated cART for the first time in BC between 2003
and 2012. The baseline characteristics, summarized in
Table 1, show that the majority of PLWH were male
(82 %), had age between 25 and 44 years, initiated
cART between 2009 and 2012, had baseline CD4 cell
count between 50 and 349 cells/mm3 and plasma viral
load greater or equal to 5.00 log10 copies/mL. The
median follow-up of these individuals was 4.5 years
(25th – 75th percentile: 2.4 – 6.8 years).
Migration patterns
There is considerable heterogeneity in physician avail-
ability (i.e. per-capita rates per 100 PLWH ever on
cART) across all HAs. As illustrated in Fig. 1, when
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physician availability was calculated according to the
HA of PLWH residence, for every one physician, HA
1 had approximately 2.4 PLWH, HA 2 had 9.0, HA 3
had 10.3, HA 4 had 4.4 and HA 5 had 4.5. In con-
trast, when physician availability was calculated using
the HA where PLWH received care, the per capita
rates slightly dropped in all HAs with the exception
of HA 2 which significantly dropped to 3.8 (57 % de-
crease), HA 5 which dropped to 3.5 (21 % decrease)
and HA 3 which increased to 12.7 (23 % increase).
Table 2A shows the distribution of PLWH according to
their residence and to where they received care during the
study period. We observed that in HAs 1, 4, and 5,
between 4 and 10 % of PLWH migrated to HA 3 (i.e. the
largest urban center) to receive care, and for HA 2 this
proportion increased to 21 %. In HA 3, 77 % of its PLWH
residents remained in the same HA for their care.
Consequently, we obtained a negative net-migration
rate of −70.0, −75.8, and −248.2 per 1000 PLWH on
cART for the HAs 1, 4 and 5, respectively, indicating
that PLWH were leaving these HAs at a higher rate
than staying in them (Table 2B). HA 3 had a net-
migration rate of 186.6 per 1000 PLWH on cART
showing that this HA is absorbing most PLWH mi-
grating for care across BC. Interestingly, HA 2 had
the highest negative net-migration rate (−1.334.4),
with most of its PLWH residents leaving to receive
care in HA 3.
Migration and HIV outcomes
At the end of follow-up, we observed 421 deaths during
17430 person-years for a crude mortality rate 24.15 per
1000 person-years (95 % confidence interval (CI)
21.90 – 26.57). A total of 666 (18 %) PLWH were lost
to follow-up, and of these, 157 (24 %) were LTFU because
they moved out of BC. After correcting the data for loss
to follow-up, we re-coded 77 PLWH as being dead at the
end of follow-up. Thus, during follow-up there were 498
deaths for a (adjusted) crude mortality rate 28.57 per 1000
person-years (95 % CI 26.12 – 31.19), and corresponding
life expectancy (at the age 20 years) of 34.53 years (stand-
ard error 1.09) (Table 3).
As illustrated in Fig. 2, there was no statistically signifi-
cant difference in suppression status among PLWH
according to whether or not they received care in the HA
of residence. We also calculated the mortality rate (per
1000 person-years) and life expectancy (at age 20 years)
for each HA according to the patient and physician
address during 2003–2012 (Table 3). When we used the
patient’s residence, HA 5 had the highest mortality rate
(53.08) and the lowest life expectancy at age 20 years
(19.41); HA 3 has the lowest mortality rate (25.84) and the
highest life expectancy at age 20 years (37.66) in the prov-
ince. When we classified PLWH according to the HA they
received care, HA 5 was the only region that experienced
the highest increase in mortality rate (62.99; 19 %
increase) and a higher decline in life expectancy at age
20 years (17.35; 11 % decrease). We found that HAs 1, 2,
3 and 4 had similar life expectancies regardless of where
PLWH lived or sought care; however the same was not
seen when we looked at the mortality rates in each of
these regions. While the mortality rate in HAs 1 and 3
decreased to 36.15 (6 % decrease) and 24.72 (4 %
decrease), respectively, the mortality rate in HAs 2 and 4
increased substantially to 31.09 (19 % decrease) and 39.10
(14 % decrease), respectively.
Figure 3 presents trends in mortality rates according
to the cART expansion eras from 2003 to 2012. This
figure also highlights the regions that were targeted
by the STOP HIV/AIDS initiative (in green) and
shows that the heterogeneity in mortality rates across
Table 1 Characteristics of the study population at the start of
combination antiretroviral therapy from 2003 to 2012 in British
Columbia
Covariates and outcomes Frequency (%) or
Median (Q1 - Q3)
Gender
Male 2979 (82 %)
Female 674 (18 %)
cART era
2003 - 2007 1554 (43 %)
2008 - 2012 2099 (57 %)
Age (years)
20 - 24 109 (3 %)
25 - 44 2138 (59 %)
45 - 64 1324 (36 %)
65 + 82 (2 %)
CD4 cell count (cells/mm3)
<50 421 (12 %)
50 - 199 1154 (32 %)
200 - 349 1172 (32 %)
350+ 906 (25 %)
Viral load (log10copies/mL)
<5.00 1545 (42 %)
5.00+ 2108 (58 %)
Adherence to therapy during the first year on cART (%)
≥95 % 2464 (67 %)
80 - <95 % 501 (14 %)
40 - <80 % 468 (13 %)
0 - <40 % 220 (6 %)
Follow-up (person-years) 4.50 (2.40 - 6.80)
cART combination antiretroviral therapy; Q1 stands for 25
th percentile; Q3
stands for 75th percentile
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BC has decreased over time especially during 2009–2012
(coefficient of variation ranged from 0.49 (in 2003–2007)
to 0.36 (in 2008–2012)). This decline was even more pro-
nounced in the HAs initially targeted by the STOP HIV/
AIDS initiative, with the mortality rate in HA 3 dropping
from 31.58 (in 2003–2007) to 17.01 (in 2008–2012) per
1000 person-years (46 % decrease; p-value <0.0001); and
HA 5 from 85.14 (in 2003–2007) to 30.28 (in 2008–2012)
per 1000 person-years (64 % decrease; p-value = 0.0041).
We also observed a significant decrease in HA 2 from
33.61 (in 2003–2007) to 14.40 (in 2008–2012) per 1000
person-years (57 % decrease; p-value = 0.0005).
Discussion
Our results demonstrate that there is a substantial hetero-
geneity in the number of PLWH seeking medical care out-
side the HA where they resided; between 4 and 21 % of
PLWH in each HA migrated to HA 3, which hosts
the province’s largest HIV care center. Although we
investigated whether out-migration rates in these re-
gions were due to physician availability, we observed
that physicians working outside HA 3 were caring for
fewer PLWH as many of their patients were seeking
care in HA 3. Additionally, we assessed whether or
not this migration for care was associated with health
Fig. 1 Physician per capita rates by Health Authority in British Columbia from 2003 to 2012. PLWH stands for persons living with HIV
Table 2 Inter-Health Authority migration rates per 1000 population in British Columbia from 2003 to 2012
Health Authority where
PLWH received care
Health Authority where PLWH resided
1 2 3 4 5 Total
1 145 6 39 6 1 197
2 11 231 477 10 4 733
3 19 65 2,027 37 6 2,154
4 3 5 75 299 1 383
5 6 7 30 4 129 176
Total 184 314 2,648 356 141 3,643
Health Authority Population at risk In-Migrants Out-Migrants In-migration rate Out-migration rate Net-migration rate
1 184 39 52 212.0 282.6 −70.7
2 314 83 502 264.3 1,598.7 −1334.4
3 2,648 621 127 234.5 48.0 186.6
4 356 57 84 160.1 236.0 −75.8
5 141 12 47 85.1 333.3 −248.2
PLWH stands for persons living with HIV
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outcomes. We observed that while migrating to a
larger center for HIV care (i.e. HA 3) was not associ-
ated with higher rates of viral load suppression; it was
significantly associated with lower mortality rates, and
slightly higher life expectancies. Finally, during the study
period, we demonstrated that mortality rates decreased
significantly in HAs 2, 3 and 5.
We hypothesized that receiving community-based
HIV care would be associated with better outcomes,
given the previous evidence from other chronic diseases
which suggested that access to a local, continuous care
provider was associated with better adherence to treat-
ment, follow-up, and overall health [7–11]. Our findings
are, therefore, in direct contrast to our initial hypothesis.
There are a number of possible explanations for these
discrepancies. First, there are potential confounding vari-
ables that may explain the association between migration
and decreased mortality, such as the differential in
Table 3 Mortality rates and life expectancies for PLWH who have ever initiated combination antiretroviral therapy from 2003 to 2012,
stratified by Health Authority
Mortality outcomes Population size Observed deaths Follow-up
(person-years)
Mortality rate (95 % CI)
per 1000 person-years
Life expectancy at age
20 years (standard error)
British Columbia 3653 498 17430 28.57 (26.12 − 31.19) 34.53 (1.09)
Health Authority
where PLWH resided
1 198 36 937 38.42 (26.91 − 53.19) 32.96 (2.82)
2 735 94 3591 26.18 (21.15 − 32.03) 34.36 (2.67)
3 2155 266 10294 25.84 (22.83 − 29.14) 37.66 (1.53)
4 386 66 1931 34.18 (26.43 − 43.48) 33.50 (2.54)
5 179 36 678 53.08 (37.19 − 73.51) 19.41 (3.38)
Health Authority
where PLWH received care
1 184 32 885 36.15 (24.73 − 51.05) 34.74 (2.96)
2 314 45 1447 31.09 (22.68 − 41.61) 34.11 (3.87)
3 2648 316 12781 24.72 (22.07 − 27.61) 37.32 (1.35)
4 356 68 1739 39.10 (30.37 − 49.57) 33.40 (2.20)
5 141 33 524 62.99 (43.35 − 88.44) 17.35 (3.67)
PLWH stands for persons living with HIV
Fig. 2 Distribution of PLWH according to suppression status at the end of follow-up by Health Authority in British Columbia from 2003 to 2012.
PLWH stands for persons living with HIV
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socio-determinants of health across HAs in BC. Add-
itionally, it is common for PLWH to move to regions
with larger centers for HIV care when they are really
sick, and for these individuals to move back to their
originating regions when they are close to dying [34]. Sec-
ond, we assumed that the lower mortality associated with
receiving care in the largest urban center in BC was
mostly due to the larger availability of medical experts. It
is important to mention that HA 3 also offers many non-
medical services for PLWH, such as housing, addictions
and psychological support, as well as, support groups and
peer networks. These other medical and non-medical
services may partially explain the better outcomes seen in
HA 3. Further studies will be needed to fully understand
the reasons for this type of migration in BC.
Our study has a number of important strengths. There
are very few studies in resource-rich settings examining
the association of migration among PLWH and health
outcomes [10, 34–39]. This is the first study to demon-
strate the relationship between migrating for HIV care
and mortality during the modern cART era and within a
treatment rollout program in BC. Also, we looked at a
large sample of PLWH receiving care within a province-
wide program, where all patients can access free medical
attention, cART, and laboratory monitoring. Thus, it is
unlikely that our results were influenced by sample size
issues or biased by direct financial limitations to access
medical care. It is also important to mention that
delayed reporting of deaths was not likely a factor to
influence our results, since most deaths were reported
within one month through active follow-up with phy-
sicians and regular linkages to the BC Vital Statistics
Agency. We also identified that a large number of PLWH
are migrating to different HAs for care, and therefore, given
that the life expectancy of PLWH is steadily increasing over
time, the continual migration of these individuals can
potentially overburden the resources of the receiving HAs.
We believe that the results from this study can inform
resource allocation in BC. Additionally, the methods used
in this study can be further utilized to assess the impact of
migration among PLWH in other settings around the
world. Lastly, this study was possible since we maintain a
state-of-art population-based database with detailed and
up-to-date information on patient and physician addresses.
On the other hand, our study has a number of
potential limitations. We did not control for physician
experience since there is no gold-standard measure avail-
able for this purpose. We also did not expand our analyses
to control for patient characteristics that may confound
the relationship between migration for care and health
outcomes. For example, it is well-known that for a patient
to successfully supress their viral load, they must be diag-
nosed and initiated on cART in a timely basis, they need
to maintain long-term optimal adherence to their treat-
ment, and it is expected that they see their follow-up
physician regularly to renew their cART prescriptions and
monitor the safety and efficacy of their treatment [5]. The
personal circumstances and attributes that allow a
Fig. 3 Mortality rate by combination antiretroviral therapyera and by the Health Authority where the patient received care in British Columbia
from 2003 to 2012. cART combination antiretroviral therapy; stands for PLWH stands for persons living with HIV; STD stands for standard deviation
(higher values means more variation); CV stands for coefficient of variation (higher values means more variation). Red bars represent the Health
Authorities that were not targeted by the intervention STOP HIV/AIDS, and green bars represent the Health Authorities targeted by this intervention
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patient to meet these requirements, including finan-
cial resources, independence, and stability may have con-
founded our results. Additionally, these results may have
been influenced by the perceived stigma/discrimination
that some PLWH might experience in smaller communi-
ties [19, 25]. Another limitation in these analyses relates
to 18 % of PLWH in our study being lost to follow-up.
Although we adjusted our data by means of a highly pre-
dictive statistical model, we continue to conduct ongoing
linkages with the BC Vital Statistics Agency to ascertain
the health status of these individuals in our database.
Finally, there are a number of ancillary non-medical
services offered in larger treatment centres to PLWH that
are not available in smaller centres, and these services are
known to potentially impact health outcomes. However, it
is unclear to what extent these services may explain the
association between migration and study outcomes.
Conclusions
The current study revealed that a significant number of
PLWH are migrating for care towards larger urban cen-
ters in BC and that this migration was associated with
decreased mortality. These findings are in contrast to
the experience in other chronic disease areas, and as
such have important implications for health policy and
resource allocation. Further research will be required to
identify what factors are associated with migration for
care, and whether these factors are independently pro-
tective against mortality. A thorough understanding of
these issues will be critical to inform resource allocation
aimed at optimizing the impact of cART.
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